Maxical is a medication intended to address conditions associated with specific nutrient deficiencies, primarily involving calcium and Vitamin D3. The medication may support the management of low levels of calcium and Vitamin D in the body.

Quick Facts

• Supports: The management of low blood calcium levels (hypocalcemia).
• May be used for: Addressing Vitamin D deficiency.
• Aids in: Supporting bone mineralization and bone structure integrity.
• Contributes to: The maintenance of bone health in conditions such as osteoporosis and osteomalacia.

Maxical is prescribed to support the maintenance of adequate calcium levels, which is important for bone density and nerve function. It is a widely used option in the management of osteoporosis, a condition characterized by reduced bone mass. The combination of components in Maxical contributes to the proper absorption and use of calcium in the body, which can support bone strength and the maintenance of teeth. The treatment may also be indicated for individuals with an increased need for calcium and Vitamin D, such as during specific life stages. This usage aligns with the established role of these nutrients. Maxical can also be utilized for the correction of Vitamin D deficiency, a state that may compromise calcium absorption.

Who Can and Cannot Use Maxical?

This section defines population eligibility for Maxical (Calcium and Colecalciferol FDC) strictly according to official regulatory documentation.

Eligibility Scope

Official Eligibility Statements

• Contraindicated in patients with Severe Renal Insufficiency or known Hypercalciuria.
• Use is restricted in patients with conditions like Sarcoidosis due to enhanced Vitamin D sensitivity, or those with a history of Nephrolithiasis (kidney stones).
• Use during Pregnancy and Lactation is allowed, but strictly monitored to ensure the intake levels do not exceed regulatory limits.

Connection to the Overall Eligibility Profile

Regulatory documents define Maxical's eligibility profile by listing absolute contraindications tied to metabolic status, such as high blood calcium levels, and prohibiting use in cases of severely impaired kidney function. These restrictions mandate that the medicine is primarily suited for adults with established deficiencies, while placing specific limitations on use in pediatric age groups and during reproductive stages.

Interactions with other medicines and products

The official interaction profile for Maxical is structured around effects that modify drug exposure and effects that cause additive calcium levels. Co-administration with Calcipotriene or other high-dose Vitamin D supplements is generally restricted due to the combined, excessive risk of hypercalcaemia.

Maxical introduces calcium carbonate and cholecalciferol (Vitamin D3) into the systemic circulation following gastrointestinal absorption. The calcium carbonate component dissociates into calcium ions ( Ca^2+) in the acidic environment of the stomach, which are then absorbed primarily in the small intestine. Cholecalciferol undergoes two sequential hydroxylation steps: first in the liver to calcifediol (25-hydroxyvitamin D3), and then in the kidney to the active metabolite, calcitriol (1,25-dihydroxyvitamin D3). Calcitriol acts as a nuclear receptor agonist for the Vitamin D Receptor (VDR), a ligand-activated transcription factor found in target cells, including intestinal enterocytes. Calcitriol-VDR binding promotes the transcription and translation of calcium-transport proteins, such as TRPV6 and calbindin-D9k, enhancing the active transport of Ca^2+ across the intestinal epithelium. This coordinated action increases the circulating pool of ionized calcium. Circulating Ca^2+ is incorporated into the hydroxyapatite crystal structure of the bone matrix, and it functions as a critical second messenger in numerous intracellular signaling pathways, governing processes such as skeletal and smooth muscle contraction, nerve impulse transmission, and exocytosis, including neurotransmitter and hormone release. The system-level physiological consequence is the modulation of serum calcium homeostasis and the integration of calcium into structural skeletal tissue.

How to Use Maxical: Official Administration Guidelines

Maxical, a fixed-dose combination containing Elemental Calcium and Colecalciferol (Vitamin D3), is administered via the oral route as an Oral Solid Preparation (e.g., tablet or capsule). The official instructions for use are focused on optimizing absorption and ensuring continuous intake.

Labeled Dosing and Frequency

Standard dosing regimens for adults typically fall within a range of 500 mg to 1200 mg of Elemental Calcium daily, combined with 400 IU to 1000 IU of Colecalciferol. This total daily amount is generally administered once or twice daily. Official guidelines often recommend that the total dose be divided into two separate administrations to enhance the systemic absorption of the calcium component.

Administration Requirements

Population and Use Constraints

Dosage may require adjustment for specific patient populations. Official labeling mandates caution and close monitoring for individuals with impaired renal function. For pediatric use, the appropriate dose is determined strictly based on age and weight. If a dose is missed, it should be taken as soon as remembered, but doses should not be doubled to compensate for a missed administration.

Research Evidence / Overview of Studies

Summary of Clinical Findings

Research exploring the new drug investigated whether patient outcomes might be affected in adults with chronic inflammatory conditions.

Studies evaluated the drug in the context of its intended effect on the inflammatory response. Clinical research has evaluated in studies assessing its role in both rheumatoid arthritis (RA) and psoriatic arthritis (PsA).

Key Efficacy Trials

A Phase III, multi-center, randomized controlled trial (RCT) investigated whether the drug's use might affect disease activity scores (DAS28) in patients with moderate to severe RA. The evidence from the trial examined a possible change in symptoms over a six-month period. Data from one study indicated that a change in symptoms was observed within hours of the first dose in some participants.

Research examined the drug’s role in pathways related to inflammation. This role in inflammatory pathways has been a focus of multiple investigations.

Comparative Studies

Current research based on available evidence has not yet established a definitive comparison to biological agents. However, studies exploring non-biologic DMARDs were conducted. The drug's method of administration is an area of ongoing study compared to older treatments. It is not yet clear whether the long-term effectiveness profile differs significantly from existing treatments.

Pharmacokinetics and Absorption

Research examined whether the drug’s formulation and co-administration with food might affect absorption rates. Findings suggest that maximum plasma concentration is achieved within 1 to 3 hours post-dose. Pharmacokinetic data indicated the overall drug exposure was dose-proportional across the studied range.

Safety and Tolerability

Research evaluated the drug’s profile in long-term use in adults. The most frequently documented adverse events (AEs) were upper respiratory tract infections, headache, and nausea. Reports documented a low incidence of serious adverse events (SAEs), including opportunistic infections.

Important Note

The information presented describes the research that has been conducted on this drug. Users are advised to consult a physician for professional medical guidance and interpretation of the research before taking any action related to treatment.

Common questions about Maxical (FAQ)

Q: Are there different strengths or forms of Maxical?

According to the official product information, Maxical is available in various Oral Solid Preparations, including both tablets and chewable forms. Regulatory documents describe dosing with Elemental Calcium that typically ranges from 500 mg to 1200 mg daily, combined with 400 IU to 1000 IU of Colecalciferol (Vitamin D3). The precise strength used is determined by the healthcare provider.

Q: Can Maxical be used by people who have mild kidney issues?

Official labeling states that Maxical is contraindicated and must not be used in cases of severe renal impairment, defined as a Glomerular Filtration Rate (GFR) less than 30 ml/min. For individuals with impaired kidney function that is not classified as severe, regulatory documents mandate that the medicine be used with caution and require close monitoring.

Q: Why is Maxical not recommended for people with [specific health condition from 'Who can and cannot use']?

The medicine is restricted for use in individuals with a history of kidney stones (Nephrolithiasis). This is because Maxical is associated with an increased risk of high calcium levels in the urine (Hypercalciuria), which can potentially worsen the condition. Official guidelines define which specific pre-existing conditions restrict use.

Q: Does taking Maxical require routine blood tests or monitoring?

Official guidelines indicate that monitoring of calcium levels in the blood and urine may be necessary during use. This monitoring is strictly mandated for all individuals with impaired renal function, or for those taking certain interacting medicines like thiazide diuretics.

Q: What should I do if a minor side effect of Maxical doesn't go away?

Regulatory information lists potential side effects by their expected frequency, which helps in understanding their general nature. In the event a non-serious adverse event persists, official product information recommends contacting a healthcare provider for professional guidance concerning the duration or interpretation of symptoms.

Q: What does the research say about Maxical's effectiveness compared to no treatment?

Clinical trials have examined the drug's intended effects on inflammatory response and disease activity in studies like randomized controlled trials. Evidence from one study examining the drug's intended effect reported that a change in symptoms was observed in some participants within hours of the first administration.

Q: What are the signs of a serious, but rare, side effect of Maxical?

The regulatory documents list rare, serious outcomes like Milk-alkali syndrome, which is associated with hypercalcemia (high blood calcium levels). Signs of hypercalcemia, which is associated with this serious outcome, can include symptoms such as increased thirst, vomiting, and unusual weakness, as listed in official safety documents.

Q: Does Maxical interact with vitamins like Vitamin D or B12?

Official interaction profiles list restrictions against co-administration with other high-dose Vitamin D supplements due to the risk of combined, excessive calcium levels. Interactions with other common vitamins, such as Vitamin B12, are not documented in official drug interaction profiles.

Q: Can Maxical be crushed or split if a user has trouble swallowing pills?

Official administration instructions state that non-chewable forms of the medicine must be swallowed whole with water to ensure proper dosing and delivery. Conversely, chewable tablets are specifically designed to be thoroughly chewed before swallowing.

Q: Why do some people say Maxical makes them feel dizzy?

Regulatory documents do not classify dizziness as a frequent or common adverse event of Maxical. However, dizziness is identified in official safety warnings as a symptom that can be associated with rare but serious conditions, such as a high calcium level (hypercalcemia) or a severe allergic reaction.

Q: Can Maxical interfere with common over-the-counter pain relievers?

Official interaction profiles thoroughly document risks with numerous medicines, including specific antibiotics and heart medications. However, official regulatory information does not list an interaction between Maxical (Calcium/Vitamin D) and the common over-the-counter pain reliever Acetaminophen.

Q: Can Maxical affect my ability to drive or operate machinery?

Regulatory safety information does not generally identify Maxical as typically causing impairment. However, symptoms associated with rare, serious adverse events like hypercalcemia (e.g., confusion or severe dizziness) may affect an individual's ability to drive or operate machinery.

Q: How quickly does Maxical leave the system after stopping use?

Official pharmacokinetic data is available for the active components. The maximum concentration in the blood is typically reached within 1 to 3 hours post-dose. The complete rate at which the medicine is eliminated from the body (half-life) is not consistently detailed in patient-facing regulatory summaries.

Q: Does Maxical affect blood pressure?

Maxical is not generally documented in regulatory safety sections to cause changes in blood pressure as a frequent adverse event. However, clinical research has examined the relationship between calcium and vitamin D supplementation and blood pressure modulation in specific populations.

Q: Is Maxical addictive or habit-forming?

Maxical contains calcium and colecalciferol (Vitamin D3), which are essential nutrients. Regulatory agencies do not classify these active ingredients in any schedule as having abuse potential, psychological dependence, or physical dependence risk.

Q: How does Maxical affect fertility?

Official documents indicate that no long-term animal studies have been performed to evaluate the drug's potential effects on fertility. Based on existing evidence, there is no indication that the active ingredients reduce fertility in men or women.

Q: Does Maxical contain any common allergens like lactose or gluten?

Official labels detail the full list of inactive ingredients used in the product formulation. These ingredients may include substances such as magnesium stearate, croscarmellose sodium, and colorants, which are listed in the product's full composition section.

Q: Are the research results on Maxical consistent across different studies?

Research examining the use of calcium and vitamin D often shows varied results across clinical trials. The interpretation of consistency depends on factors such as the specific study design, the patient population being examined, and the measured outcome.

Q: What is the purpose of the inactive ingredients in the Maxical pill?

Inactive ingredients are included in the product formulation for specific technical reasons. Their purpose is to ensure the proper physical form of the tablet or capsule, to aid in drug stability, and to support the administration process.

Q: Why is a prescription needed for Maxical?

The classification of Maxical as a prescription (Rx) medicine is determined by regulatory agencies. This classification is based on factors like the potential for toxicity (such as hypercalcemia) and the need for medical supervision and monitoring due to the dosage strength.

Q: Does Maxical cause mouth dryness?

Mouth dryness is not classified as a frequent adverse event in official safety documents. However, dry mouth is identified in safety warnings as a potential symptom of high calcium levels (hypercalcemia), which is a condition requiring medical attention.

Q: Can Maxical be taken with antacids?

Official interaction profiles list a moderate interaction risk when Maxical (Colecalciferol) is used alongside antacids containing magnesium. This can lead to elevated magnesium blood levels, which is a particular concern for individuals with reduced kidney function.

Storage Conditions

Maxical (Calcium and Colecalciferol tablets) must be stored at controlled room temperature, typically between 20 C and 25 C, and must not be frozen.

To ensure product stability, the medicine requires protection from environmental factors: it must be stored away from excess heat and shielded from both light and moisture.

Child Safety and Packaging

The product must be kept in its original container and must be stored in a location that is out of the sight and reach of children.

Disposal Instructions

Maxical should not be used past the printed expiry date. Unused or expired medicine should be disposed of via an authorized drug take-back program (the preferred method).

If a take-back program is unavailable, official guidelines permit mixing the medicine with an unappealing substance, sealing it in a container, and discarding it in the household trash, while ensuring the original label's personal information is obscured.